Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient

AIDS

Volumn 26, Issue 18, 2012, Pages 2417-2418

  Lorenzini, Kuntheavy I ^a   Calmy, Alexandra ^a   Ambrosioni, Juan ^a   Assouline, Benjamin ^a   Daali, Youssef ^a   Fathi, Marc ^a   Rebsamen, Michela ^a   Desmeules, Jules ^a   Samer, Caroline F ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DARUNAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ESCITALOPRAM; ESOMEPRAZOLE; RITONAVIR;

ADULT; CASE REPORT; DEPRESSION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; GASTROESOPHAGEAL REFLUX; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIVER CIRRHOSIS; MIXED INFECTION; PHENOTYPE; PRIORITY JOURNAL; SEROTONIN SYNDROME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARYL HYDROCARBON HYDROXYLASES; CITALOPRAM; COINFECTION; CYTOCHROME P-450 CYP2D6; DEPRESSION; DRUG INTERACTIONS; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RITONAVIR; SEROTONIN SYNDROME; SULFONAMIDES;

EID: 84870196606     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835a11ba     Document Type: Letter

References (18)

1. Watkins CC, Pieper AA, Treisman GJ. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. Drug Saf 2011;34:623-639.
2. Rebsamen MC, Desmeules J, Daali Y, Chiappe A, Diemand A, Rey C, et al. The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction. Pharmacogenomics J 2009;9:34-41.
3. Daali Y, Cherkaoui S, Doffey-Lazeyras F, Dayer P, Desmeules JA. Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. J Chromatogr B Analyt Technol Biomed Life Sci 2008;861:56-63. (Pubitemid 50009267)
4. Jerdi MC, Daali Y, Oestreicher MK, Cherkaoui S, Dayer P. A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes. J Pharm Biomed Anal 2004;35:1203-1212. (Pubitemid 39140285)
5. Daali Y, Samer C, Deglon J, Thomas A, Chabert J, Rebsamen M, et al. Oral flurbiprofen metabolic ratio assessment using a single-point dried blood spot. Clin Pharmacol Ther 2012;91:489-496.
6. Sangkuhl K, Klein TE, Altman RB. PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics 2011;21:769-772.
7. Noehr-Jensen L, Zwisler ST, Larsen F, Sindrup SH, Damkier P, Nielsen F, et al. Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker. Eur J Clin Pharmacol 2009;65:887-894.
8. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-290. (Pubitemid 46507007)
9. Rocha A, Coelho EB, Sampaio SA, Lanchote VL. Omeprazole preferentially inhibits the metabolism of (R) - (S)-citalopram in healthy volunteers. Br J Clin Pharmacol 2010;70:43-51.
10. Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos 2011;39:2020-2033.
11. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 2011;90:666-673.
12. Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A 2010;107:18422- 18427.
13. Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739-756. (Pubitemid 47347446)
14. Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9M3 allele. Pharmacogenomics 2012;13:757-762.
15. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352:1112-1120.
16. Talarico G, Tosto G, Pietracupa S, Piacentini E, Canevelli M, Lenzi GL, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci 2011;32:507-509.
17. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010;15:413-423.
18. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, et al. Pharmacogenetics: from bench to byte: an update of guidelines. Clin Pharmacol Ther 2011;89:662-673.